Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia

Published:2020-01-30 Issue:7 Volume:55 Page:1410-1420
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Wethmar Klaus,Matern Svenja,Eßeling Eva,Angenendt Linus,Pfeifer Heike,Brüggemann Monika,Stelmach Patrick,Call Simon,Albring Jörn C.,Mikesch Jan-Henrik,Reicherts Christian,Groth Christoph,Schliemann Christoph,Berdel Wolfgang E.,Lenz Georg,Stelljes Matthias

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-0801-0.pdf

Reference48 articles.

1. Giebel S, Labopin M, Socie G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139–49. https://doi.org/10.3324/haematol.2016.145631

2. Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524–33. https://doi.org/10.3324/haematol.2016.144311

3. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl J Med. 2016;375:740–53. https://doi.org/10.1056/NEJMoa1509277

4. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl J Med. 2017;376:836–47. https://doi.org/10.1056/NEJMoa1609783

5. Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23. https://doi.org/10.1182/blood-2005-07-2708

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation;Cells;2024-06-06

2. Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation;Frontiers in Oncology;2023-02-22

3. Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions;OncoTargets and Therapy;2023-01

4. Significance and methods of chimerism analysis after allogeneic hematopoietic stem cell transplantation;Japanese Journal of Transplantation and Cellular Therapy;2023

5. Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage‐specific chimerism analysis;eJHaem;2022-09-19